We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System
Product News

Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System

Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System
Product News

Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TAP Biosystems has announced that its new ambr250™ automated mini bioreactor system has already been chosen by a number of major pharmaceutical, biotech and CRO firms as a high-throughput, scale-down bioreactor model for their process development and optimization programmes.

The automated ambr250 system, which has independent parallel control of 12 or 24, single-use 250 mL bioreactors, is being sited at the R&D centres of the top Pharma companies across the US and Europe. The system has also been chosen for the Chinese R & D centre of a major European biopharm; a major CRO in the UK and a UK-based biotech company.

The majority of these systems will be used to accelerate mammalian and microbial process development and optimization of antibody and other protein-based therapeutics. However, three of the systems will be utilized in rapidly developing process optimization for the production of vaccines.

The companies have chosen the ambr 250 because the high-throughput system has the flexibility to culture mammalian lines including CHO or microbial cells such as Pichia pastoris and E.coli in single-use, stirred bioreactors and utilizes continuous pumped feeds, making it possible to fully evaluate the process characteristics of large scale bioreactors and fermenters.

Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems said: “The bioprocessing industry is looking for a realistic scale-down model to accelerate process development and optimize scale-up of cell culture manufacturing processes. The ambr250 system has been rigorously tested by the top pharma firms and it is our expectation that it will be widely adopted across the industry.”

Ngibuini added: “These pharma as well as, CRO and biotech firm installations demonstrate that ambr250 is well-validated, and has universal appeal as an efficient, high-throughput method of scalable process development for a range of industrial cell culture and fermentation applications.”

Advertisement